Lung Cancer
News from the FDA/CDC
FDA expands indication for pembrolizumab in NSCLC
Pembrolizumab (Keytruda) is now approved to treat patients with metastatic NSCLC whose tumors have high PD-L1 expression, with no EGFR or ALK...
Conference Coverage
Lung cancer screening found effective in a community hospital
Lung cancer screening with low-dose CT scans in a community hospital setting replicates results from international and multicenter trials when it...
From the Journals
Smoking-attributable cancer mortality highest in Kentucky
Almost 29% of cancer deaths among U.S. adults aged 35 years and older were attributable to cigarette smoking in 2014
News from the FDA/CDC
FDA approves atezolizumab for advanced NSCLC
The FDA has approved the PD-L1 blocking antibody atezolizumab for the treatment of patients with metastatic non–small-cell lung cancer whose...
Conference Coverage
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
Pembrolizumab was superior to chemotherapy in stage IV NSCLC with PD-L1 expression of 50% or more.
Conference Coverage
OAK: Atezolizumab grows OS in advanced NSCLC
COPENHAGEN – The checkpoint inhibitor atezolizumab improved overall survival of advanced non–small-cell lung cancer, compared with docetaxel.
Conference Coverage
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
COPENHAGEN – Adding the PD-1 checkpoint inhibitor pembrolizumab (Keytruda) to a standard platinum-doublet chemotherapy regimen nearly doubled...
From the Journals
Patients with stage 1 NSCLC more likely to die of other causes in short term
Patients with resected stage 1 non-small cell lung cancer are more likely to die of other causes in the short term.
Conference Coverage
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
COPENHAGEN – Checkpoint inhibitors have shown good efficacy for treatment of advanced NSCLC, but use in the neoadjuvant setting is still...